MannKind (MNKD) and its Indian partner Cipla said Wednesday that India's Central Drugs Standard Control Organization has approved Afrezza inhalation powder for adults with diabetes.
MannKind expects to ship Afrezza to Cipla by the end of 2025, the companies said.
Under an exclusive marketing and distribution agreement for Afrezza, Cipla was responsible for obtaining regulatory approvals as well as marketing and sales of Afrezza in India, while MannKind supplies the product to Cipla, according to a joint statement.
Afrezza is approved in the US and Brazil, the companies added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.